Diabetes Mellitus Clinical Trial
— sclerostinOfficial title:
The Effects of Hemodialysis on Serum Sclerostin Levels in Diabetic Patients With Chronic Renal Failure
Verified date | May 2019 |
Source | Abant Izzet Baysal University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background: Parathyroid hormone (PTH) and 1,25-dihydroxy vitamin D (1,25-OHD) as well as
mineral bone metabolism modulators like sclerostin are thought to play an important role in
in diabetic patients with chronic renal failure. The present study aimed to analyse the
levels of serum sclerostin before and after hemodialysis which is a primary element of
treatment in such combined disease states.
Methods: Serum sclerostin concentrations were measured using a commercially available
enzyme-linked immunosorbent assay kit with 56 individuals who 14 chronic hemodialysis
patients with diabetes, 14 chronic hemodialysis patients with non-diabetes and 28 healthy
volunteers as a control group.
Status | Completed |
Enrollment | 56 |
Est. completion date | December 15, 2018 |
Est. primary completion date | November 15, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 44 Years to 74 Years |
Eligibility |
Inclusion Criteria: - Patients who satisfied inclusion criteria signed informed consent forms before they enrolled in the study. - Chronic hemodialysis patients receiving treatment at our hospital. - The patients had Type 2 diabetes mellitus and the patients were not diabetic. - Healthy volunteers as a control group Exclusion Criteria: - Clinical diagnosis of chronic respiratory failure, acute kidney failure, nephrotic syndrome, end-stage liver disease, malignancy, acute infections - Any health problems necessitating urgent interventions, drinking alcohol and/or smoking as well as pregnant patients |
Country | Name | City | State |
---|---|---|---|
Turkey | Bolu Abant Izzet Baysal University | Bolu | Merkez |
Lead Sponsor | Collaborator |
---|---|
Abant Izzet Baysal University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change from levels of serum sclerostin of Diabetic group in dialysis at 1 months | Sclerostin is an anti-anabolic protein of 22-kDa size, at a level of ng/mL. Serum concentrations are measured with an ELISA kit (Cloud-CloneCorp., Katy, TX 77494, USA). | blood samples were obtained within 30 minutes of before and after dialysis | |
Primary | change from levels of serum sclerostin of Non-diabetic group in dialysis at 1 months | Sclerostin is an anti-anabolic protein of 22-kDa size, at a level of ng/mL. Serum concentrations are measured with an ELISA kit (Cloud-CloneCorp., Katy, TX 77494, USA). | blood samples were obtained within 30 minutes of before and after dialysis | |
Primary | change from levels of serum sclerostin of control group | Sclerostin is an anti-anabolic protein of 22-kDa size, at a level of ng/mL. Serum concentrations are measured with an ELISA kit (Cloud-CloneCorp., Katy, TX 77494, USA). | through study completion, an average of 1 day. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |